secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001437749-24-026166
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex granted Singapore patent for Reqorsa with anti-PD-1 antibodies through 2037
--------------------------------------------------------------------------------

- Singapore Patent Office grants patent covering Reqorsa (quaratusugene ozeplasmid) in combo with anti-PD-1 antibodies until 2037.
- Patent expands on previously granted patents in U.S., Japan, Mexico, Russia, Australia, Chile, China, and Korea.
- Korean patent also claims Reqorsa with PD-L1 antibodies; Genprex plans similar filings in U.S., Brazil, Canada, China, Europe, Israel.
- Patent supports Acclaim-3 Phase 1/2 trial for ES-SCLC maintenance therapy combining Reqorsa with Tecentriq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774924026166/0001437749-24-026166-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774924026166/gnpx20240803_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-026166

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer